Skip to main content

PHVS · Pharvaris N.V. · Documents

Track PHVS — free
$31.60 -0.06 (-0.19%)
Market Cap
$2.24B
Shares
70.79M
Volume · Nov 20 218.81K Avg daily vol (3M) 755.25K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss 175.7M EUR 20-F filed Apr 2, 2026
2026
Nov 12
Current report 6-K
Deucrictibant FDA review targets April 23, 2027

Pharvaris reported the FDA PDUFA target action date for deucrictibant IR is April 23, 2027; CREAATE part 1 topline data are expected in 1Q2027. Cash and cash equivalents were €283 million, and quarterly loss was €47.4 million.

Read from the first part of this long document
5 source passages
Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027 Topline data from part 1 of CREAATE, a pivotal Phase 3 study evaluating deucrictibant XR for the prophylaxis of AAE-C1INH attacks, expected in 1Q2027 Cash and cash equivalents were €283 million as of September 30, 2026, compared to €292 million for December 31, 2025. Loss for the quarter. Loss for the third quarter was €47.4 million, resulting in basic and diluted loss per share of €0.67 for the quarter ended September 30, 2026, compared to €37.1 million, or basic and diluted loss per share of €0.60, for the quarter ended September 30, 2025. Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the third quarter ending on September 30, 2026, and provided a business update. Open the document at this passage
Nov 9
Investor event
On-demand PDUFA date set for April 23rd, 2027

Pharvaris N.V. has an April 23rd, 2027 PDUFA date for on-demand treatment, plans CREATE topline data in the first quarter of next year, and expects parallel prophylaxis NDAs after collecting safety data in the first half of the 27th year.

3 source passages
We have a PIDUFA date for that on April 23rd, 2027. we're also going to be reading out top-line data from our CREATE study, which is the do correct demand for the prevention of acquired angioedema attacks. That'll be in the first quarter of next year. We expect we collect all the data, the first half of the 27th year, then we can submit that, you know, the NDA filing for the prophylaxis. Open the document at this passage
Apr 2
Annual report 20-F FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss 175.7M EUR Diluted EPS -2.97 EUR
2025
2024
2023
Showing 1–50 of 94 documents
Key facts CIK 1830487 CUSIP N69605108 13F (30d) 150 filings 134 filers Visit website Investor relations